¼¼°èÀÇ DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ½ÃÀå
DNA / RNA Sample Extraction and Isolation
»óǰÄÚµå : 1759008
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 479 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,112,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,338,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ¼¼°è ½ÃÀåÀº 2030³â±îÁö 36¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 27¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ¼¼°è ½ÃÀåÀº 2024-2030³â CAGR 4.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 36¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼Ò¸ðǰ Á¦°øÀº CAGR 3.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 24¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â±â Á¦°ø ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 6.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 4,140¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR7.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ½ÃÀåÀº 2024³â¿¡ 7¾ï 4,140¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 7.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 7¾ï 760¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.4%¿Í 4.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

DNA/RNA ÃßÃâÀÌ Çö´ë ºÐÀÚ»ý¹°ÇÐÀÇ ÇÙ½ÉÀÌ µÈ ÀÌÀ¯

¼¼°è DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ½ÃÀåÀº Áø´Ü, ÀǾàǰ °³¹ß, ¸ÂÃãÀÇ·á, À¯ÀüÀÚ ¿¬±¸¿¡¼­ÀÇ ±âÃÊÀûÀÎ ¿ªÇÒ·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÃßÃâ ¹× ºÐ¸® °øÁ¤Àº Ç÷¾×, Á¶Á÷, ¼¼Æ÷, º´¿øÃ¼ µî ´Ù¾çÇÑ »ý¹°ÇÐÀû »ùÇÿ¡¼­ ¼ø¼öÇÑ ÇÙ»êÀ» ¾ò±â À§ÇØ ÇʼöÀûÀ̸ç, ÀÌ´Â PCR, ½ÃÄö½Ì, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, CRISPR ÆíÁý°ú °°Àº ´Ù¿î½ºÆ®¸² ¿ëµµ¿¡ »ç¿ëµË´Ï´Ù. À¯ÀüüÇÐ ¹× Á¤¹ÐÀÇ·áÀÇ ºÕÀ¸·Î ÀÌ·¯ÇÑ ÇÁ·Î¼¼½º´Â »ý¸í°úÇÐ ¿öÅ©Ç÷οìÀÇ ÀÏ»óÀûÀ̰í Áß¿äÇÑ ±¸¼º¿ä¼Ò°¡ µÇ¾úÀ¸¸ç, Äڷγª19 ÆÒµ¥¹ÍÀº ´ë·® Áø´Ü Å×½ºÆ®¿¡¼­ °í󸮷® ÇÙ»ê ÃßÃâÀÇ Á߿伺À» ±ØÀûÀ¸·Î ºÎ°¢½ÃÄ×°í, ºÐÀÚ»ý¹°ÇÐ ½ÇÇè½ÇÀÇ ÀÎÇÁ¶ó¿Í ±â´ëÄ¡¸¦ ¿µ±¸ÀûÀ¸·Î º¯È­½ÃÄ×½À´Ï´Ù. °ú ºÐÀÚ»ý¹°ÇÐ ½ÇÇè½ÇÀÇ ÀÎÇÁ¶ó¸¦ ¿µ±¸ÀûÀ¸·Î º¯È­½ÃÄ×½À´Ï´Ù. ¿À´Ã³¯ °¨¿°¼º Áúȯ, À¯ÀüÀû ±â¹ÝÀÌ ÀÖ´Â ¸¸¼º Áúȯ, ³ó¾÷ À¯ÀüüÇÐ ºÐ¾ß Áõ°¡´Â °¢ ºÐ¾ß ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸½Ç°ú ÀÓ»ó ½ÇÇè½Ç ¸ðµÎ ´õ ºü¸¥ ó¸® ½Ã°£°ú ÀçÇö¼ºÀ» Ãß±¸Çϸ鼭 È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ÃßÃâ ±â¼úÀÇ ¿ªÇÒÀÌ ±× ¾î´À ¶§º¸´Ù Áß¿äÇØÁ³½À´Ï´Ù.

°í 󸮷® ¿¬±¸¼ÒÀÇ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ±â¼úÀº ¾î¶»°Ô ¹ßÀüÇϰí Àִ°¡?

ÇÙ»ê ÃßÃ⠺оߴ ÀÚµ¿È­, ¼ÒÇüÈ­ ¹× ´Ù¸¥ ½ÇÇè½Ç Ç÷§Æû°úÀÇ ÅëÇÕÀ» ÅëÇØ ±â¼úÀû µµ¾àÀ» ¸ñ°ÝÇß½À´Ï´Ù. Æä³î-Ŭ·Î·ÎÆ÷¸§ ÃßÃâ ¹× ½Ç¸®Ä« Ä÷³ ±â¹Ý ¹æ¹ý°ú °°Àº ÀüÅëÀûÀÎ ¼öµ¿ ±â¼úÀº ÇöÀç ¸¶±×³×ƽ ºñµå ±â¹Ý ÀÚµ¿È­ ½Ã½ºÅÛÀ¸·Î º¸¿ÏµÇ°í Á¾Á¾ ´ëüµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÚµ¿È­ Ç÷§ÆûÀº ´õ ³ôÀº 󸮷®, ´õ ³ªÀº Àϰü¼º ¹× ¿À¿° Á¦¾î¸¦ Á¦°øÇÏ¿© ÀÓ»ó ¹× »ê¾÷ ±Ô¸ðÀÇ ½ÇÇè½Ç¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ¶ÇÇÑ, īƮ¸®Áö ±â¹Ý ÃßÃâ ŰƮ´Â ƯÈ÷ °¨¿°¼º Áúȯ °Ë»ç¿¡¼­ ÇöÀå Áø·á ¹× ºÐ»êµÈ ȯ°æ¿¡¼­ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ÃÖ±ÙÀÇ ±â¼ú Çõ½Å¿¡´Â ¹Ì¼¼ À¯Ã¼ ½Ã½ºÅÛ°ú °áÇÕ È­ÇÐÀ» °­È­ÇÑ °íü»ó ÃßÃâÀÌ Æ÷ÇÔµÇ¾î ¹Ì·® ½Ã·á ¹× ¿­È­µÈ ½Ã·á¿¡¼­µµ ³ôÀº °¨µµ¿Í ȸ¼öÀ²À» ´Þ¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ÇöÀç ´Ù¾çÇÑ À¯ÇüÀÇ ½Ã·á¿¡ ´ëÀÀÇÏ´Â ½Ã¾à ŰƮ ¼³°è¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ¿¬±¸ÀÚµéÀÌ ÃÖ¼ÒÇÑÀÇ À籸¼ºÀ¸·Î DNA¿Í RNA ÇÁ·ÎÅäÄÝÀ» ÀüȯÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ÃßÃ⠽ýºÅÛ°ú ½Ç½Ã°£ PCR ¹× ½ÃÄö½Ì ÆÄÀÌÇÁ¶óÀΰúÀÇ ÅëÇÕÀº ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ¿© ºÐÀÚÁø´ÜÀ» ±× ¾î´À ¶§º¸´Ù ºü¸£°í È¿À²ÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù.

½ÃÀå °¡¼ÓÈ­ÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â ÃÖÁ¾ »ç¿ë ºÐ¾ß¿Í Áö¿ªÀº?

ÀÓ»ó Áø´Ü, Çмú ¿¬±¸, ¹ÙÀÌ¿À ÀǾàǰ °³¹ßÀº DNA/RNA ÃßÃâ ½ÃÀåÀ» °ßÀÎÇÏ´Â ÇÙ½É ÃÖÁ¾ ¿ëµµ ºÐ¾ßÀÔ´Ï´Ù. ÀÓ»ó ½ÇÇè½Ç, ƯÈ÷ Á¾¾çÇÐ, °¨¿° ¹× À¯Àü¼º ÁúȯÀ» °Ë»çÇÏ´Â °Ë»ç½ÇÀº ÇÙ»ê ÃßÃâ ŰƮ ¹× ±â±âÀÇ °¡Àå Å« ¼ö¿äó Áß ÇϳªÀÔ´Ï´Ù. Çмú ±â°ü°ú Á¤ºÎ Áö¿ø ±â°üÀº À¯ÀüüÇÐ, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸, ÁøÈ­ »ý¹°Çп¡ ´ëÇÑ ÅõÀÚ¸¦ ÅëÇØ Áö¼ÓÀûÀ¸·Î Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à »ê¾÷Àº ½Å¾à °³¹ß¿¡¼­ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¸ð´ÏÅ͸µ¿¡ À̸£±â±îÁö ¸ðµç ´Ü°è¿¡¼­ DNA/RNA ÃßÃâ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Áö¸®ÀûÀ¸·Î ºÏ¹Ì´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ¿¬±¸ ÀÚ±Ý, źźÇÑ »ý¸í°øÇÐ ºÎ¹®¿¡ ÈûÀÔ¾î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º¿¡¼­ Ȱ¹ßÇÑ ¼ö¿ä°¡ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹, ÀϺ», Çѱ¹, Àεµ µîÀÇ ±¹°¡µéÀÌ ÀÓ»ó Áø´Ü ¿ª·® È®´ë¿Í À¯Àüü ¿¬±¸ ³ë·Â¿¡ ÈûÀÔ¾î äÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À °æÁ¦ Àü·«°ú ½ÅÈï±¹ÀÇ Áúº´ ÅðÄ¡¸¦ À§ÇÑ Á¤ºÎ Áö¿øµµ ÀÌ Áö¿ª ½ÃÀå °³Ã´À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

DNA/RNA »ùÇà ÃßÃâ ¹× ºÐ¸® ½ÃÀåÀÇ ¼ºÀåÀº ºÐÀÚÁø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, À¯Àüü ¿¬±¸ ÇÁ·Î±×·¥ÀÇ Æø¹ßÀûÀÎ Áõ°¡, °¨¿°¼º ¹× À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¸¶±×³×ƽ ºñµå ±â¹Ý ÃßÃâ, ÀÚµ¿È­ Ç÷§Æû, ½Ã¾à ÃÖÀûÈ­ µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î È¿À²¼º, 󸮷®, Á¤È®µµ°¡ Å©°Ô Çâ»óµÇ¾î ÀÓ»ó ¹× ¿¬±¸ ȯ°æ ¸ðµÎ¿¡¼­ Æø³Ð°Ô µµÀԵǰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í µ¿¹Ý Áø´ÜÀÇ ±ÞÁõÀ¸·Î Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â °íǰÁú ÇÙ»êÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄɾî ÀÎÇÁ¶ó ¹× »ý¸í°úÇÐ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ±â¾÷ÀÇ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î ½ÇÇè½ÇÀÇ ¿ë·®ÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀçÅà À¯ÀüÀÚ °Ë»ç ¹× ÈÞ´ë¿ë PCR Àåºñ¿Í °°Àº ºÐ»êÇü Áø´Ü Áõ°¡ Ãß¼¼µµ »ç¿ëÇϱ⠽¬¿î ÃßÃâ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ÇÙ»ê ÃßÃâÀÌ »ùÇÿ¡¼­ °á°ú±îÁöÀÇ Àüü ¿öÅ©Ç÷ο쿡 ÅëÇյǸ鼭 ÇÙ»ê ÃßÃâÀº Áø´Ü, ¹ýÀÇÇÐ, ³ó¾÷, ȯ°æ ºÐ¾ß Àü¹Ý¿¡ °ÉÃÄ ÇÙ½É ±â¼ú·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

ºÎ¹®

Á¦°ø(¼Ò¸ðǰ, ±â±â), ±â¼ú(½Ç¸®Ä« ±â¹Ý ±â¼ú, ÀÚ¼º ÀÔÀÚ ±â¼ú, ÀÚµ¿ ½ºÇÉ Ä÷³ ±â¹Ý ±â¼ú, ÀÚ¼º ºñÁî ±â¹Ý ±â¼ú, ÀÚµ¿ ¸®Å°µå Çڵ鸵 ±â¼ú, ±âŸ ±â¼ú), ¿ëµµ(PCR ¿ëµµ, NGS ¿ëµµ, Ŭ·Î´× ¿ëµµ, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ¿ëµµ, ºê·ÔÆÃ ±â¼ú ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(ÀÓ»ó Áø´Ü£¦¹ýÀÇÇÐ ¿¬±¸¼Ò ÃÖÁ¾ ¿ëµµ, Á¦¾à£¦¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, °è¾à ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 32°³»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global DNA / RNA Sample Extraction and Isolation Market to Reach US$3.6 Billion by 2030

The global market for DNA / RNA Sample Extraction and Isolation estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Consumables Offering, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Instruments Offering segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$741.4 Million While China is Forecast to Grow at 7.6% CAGR

The DNA / RNA Sample Extraction and Isolation market in the U.S. is estimated at US$741.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$707.6 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global DNA / RNA Sample Extraction and Isolation Market - Key Trends & Drivers Summarized

Why Has DNA/RNA Extraction Become a Cornerstone in Modern Molecular Biology?

The global DNA/RNA sample extraction and isolation market is expanding rapidly due to its foundational role in diagnostics, drug development, personalized medicine, and genetic research. Extraction and isolation processes are essential for obtaining pure nucleic acids from a variety of biological samples-blood, tissues, cells, or pathogens-which are then used in downstream applications such as PCR, sequencing, microarrays, and CRISPR editing. With the boom in genomics and precision medicine, these processes have become routine yet critical components of life science workflows. The COVID-19 pandemic dramatically highlighted the importance of high-throughput nucleic acid extraction in mass diagnostic testing, which permanently altered both infrastructure and expectations for molecular biology labs. Today, the global rise in infectious diseases, chronic conditions with genetic bases, and even agricultural genomics is fueling demand across sectors. As both research and clinical labs aim for faster turnaround times and reproducibility, the role of efficient, scalable extraction technologies has never been more crucial.

How Are Technologies Advancing to Meet the Demands of High-Throughput Laboratories?

The field of nucleic acid extraction has witnessed a technological leap, driven by automation, miniaturization, and integration with other lab platforms. Traditional manual techniques such as phenol-chloroform extraction or silica column-based methods are now being complemented-and often replaced-by magnetic bead-based automation systems. These automated platforms offer higher throughput, better consistency, and contamination control, making them ideal for clinical and industrial-scale labs. Additionally, cartridge-based extraction kits have gained popularity for point-of-care and decentralized settings, particularly in infectious disease testing. Recent innovations also include microfluidic systems and solid-phase extraction with enhanced binding chemistry, offering high sensitivity and recovery even from minute or degraded samples. Companies are now focusing on designing reagent kits compatible with a wide range of sample types, enabling researchers to switch between DNA and RNA protocols with minimal reconfiguration. The integration of extraction systems with real-time PCR and sequencing pipelines is streamlining workflows, making molecular diagnostics faster and more efficient than ever before.

Which End-Use Sectors and Regions Are Driving Market Acceleration?

Clinical diagnostics, academic research, and biopharmaceutical development represent the core end-use segments that are fueling the DNA/RNA extraction market. Clinical laboratories, particularly those involved in oncology, infectious disease, and inherited disorder screening, are among the largest consumers of nucleic acid extraction kits and instruments. Academic and government-funded institutions continue to contribute significantly due to their investment in genomics, microbiome studies, and evolutionary biology. The biopharma industry relies heavily on DNA/RNA extraction in every phase from drug discovery to bioprocess monitoring. Geographically, North America dominates the market, supported by well-established healthcare infrastructure, high research funding, and a robust biotechnology sector. Europe follows closely with strong demand in the UK, Germany, and France. In Asia-Pacific, countries such as China, Japan, South Korea, and India are seeing accelerated adoption, driven by expanding clinical diagnostics capabilities and genomic initiatives. Government support for bioeconomy strategies and emerging disease preparedness is also amplifying regional market development.

What Are the Key Factors Driving Market Growth?

The growth in the DNA/RNA sample extraction and isolation market is driven by several factors, including the rising demand for molecular diagnostics, the explosion of genomic research programs, and the increasing prevalence of infectious and genetic diseases. Technological advances such as magnetic bead-based extraction, automated platforms, and reagent optimization have significantly improved efficiency, throughput, and accuracy, encouraging broader adoption in both clinical and research environments. The surge in personalized medicine and companion diagnostics has increased the need for high-quality nucleic acids to inform treatment decisions. Additionally, growing investments by governments and private entities in healthcare infrastructure and life sciences research are expanding laboratory capacities worldwide. The rising trend of decentralized diagnostics, such as home-based genetic tests and portable PCR devices, has also spurred demand for user-friendly extraction solutions. Lastly, the integration of nucleic acid extraction into complete sample-to-answer workflows is making it a linchpin technology across diagnostic, forensic, agricultural, and environmental applications.

SCOPE OF STUDY:

The report analyzes the DNA / RNA Sample Extraction and Isolation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Consumables Offering, Instruments Offering); Technology (Silica-based Technology, Magnetic Particle Technology, Automated Spin Column-based Technology, Magnetic Bead-based Technology, Automated Liquid Handling Technology, Other Technologies); Application (PCR Application, NGS Application, Cloning Application, Microarray Application, Blotting Techniques Application, Other Applications); End-Use (Clinical Diagnostic & Forensic Laboratories End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â